The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Corrigan-Curay emphasized that Journavx could “mitigate certain risks associated with using an opioid for pain.” The FDA’s official account on X also tweeted the news — the agency’s ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...
Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.